Antibody Microarrays for Cancer Diagnostics

Information

  • Research Project
  • 7253255
  • ApplicationId
    7253255
  • Core Project Number
    R44CA105540
  • Full Project Number
    5R44CA105540-03
  • Serial Number
    105540
  • FOA Number
  • Sub Project Id
  • Project Start Date
    3/1/2004 - 20 years ago
  • Project End Date
    12/31/2008 - 16 years ago
  • Program Officer Name
    WELCH, ANTHONY R
  • Budget Start Date
    7/1/2007 - 17 years ago
  • Budget End Date
    12/31/2008 - 16 years ago
  • Fiscal Year
    2007
  • Support Year
    3
  • Suffix
  • Award Notice Date
    6/7/2007 - 17 years ago

Antibody Microarrays for Cancer Diagnostics

[unreadable] DESCRIPTION (provided by applicant): This Phase II proposal follows successful Phase I studies and describes the development, optimization, scale up, and utility testing of an efficient and cost effective technology to produce and purify high quality and affordable customized scFv antibodies for use in multiplex assays such as antibody arrays. The limited quality and number of reagents available for the construction of antibody micro arrays makes them costly to produce and unreliable to use. Polyclonal and hybridoma derived monoclonal antibodies, frequently don't have the characteristics suitable for use in these micro arrays nor are amenable to molecular evolution for higher affinity and the ability to capture native proteins from solution whilst conjugated to the surface of the micro array. This proposal utilizes yeast display technology to identify, develop, and optimize production of antibody molecules that function under the conditions of the micro array assay, incorporate these into micro arrays and further validate these by using solid tumor samples. The first targets we have selected are a series of receptor tyrosine kinases and their cognate ligands that are known to be involved in multiple types of cancer and for which therapeutics are currently either marketed or in development. The development of high quality antibody reagents for use in the construction of micro arrays will have broad implications in making diagnostic and research tools. [unreadable] [unreadable]

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R44
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    386520
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:386520\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    MERRIMACK PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
    001221410
  • Organization City
    CAMBRIDGE
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02139
  • Organization District
    UNITED STATES